Abstract
Valnemulin reportedly regulates inflammatory responses in addition to its in vitro antibacterial activity. In this study, we established a mouse model of lipopolysaccharide (LPS)-induced inflammatory lung injury and investigated the effect of valnemulin (100 mg/kg) on acute lung injury (ALI) 8 h after LPS challenge. We prepared bronchoalveolar lavage fluid (BALF) for measuring protein concentrations, cytokine levels, and superoxidase dismutase (SOD) activity, and collected lungs for assaying wet-to-dry weight (W/D) ratios, myeloperoxidase (MPO) activity, cytokine mRNA expression, and histological change. We found that the pre-administration of valnemulin significantly decreases the W/D ratio of lungs, protein concentrations, and the number of total cells, neutrophils, macrophages, and leukomonocytes, and histologic analysis indicates that valnemulin significantly attenuates tissue injury. Furthermore, valnemulin significantly increases LPS-induced SOD activity in BALF and decreases lung MPO activity as well. In addition, valnemulin also inhibits the production of tumor necrosis factor-α, interleukin-6, and interleukin-1β, which is consistent with mRNA expression in lung. The results showed that valnemulin had a protective effect on LPS-induced ALI in mice.
Similar content being viewed by others
References
Fujishima, S., and N. Aikawa. 1995. Neutrophil-mediated tissue injury and its modulation. Intensive Care Medicine 21: 277–285.
Ware, L.B., and M.A. Matthay. 2000. The acute respiratory distress syndrome. New England Journal of Medicine 342: 1334–1349.
Bosma, K., V. Fanelli, and V.M. Ranieri. 2005. Acute respiratory distress syndrome: update on the latest developments in basic and clinical research. Current Opinion in Anaesthesiology 18: 137–145.
Lee, W.L., and G.P. Downey. 2001. Neutrophil activation and acute lung injury. Current Opinion in Critical Care 7: 1–7.
Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. Journal of Pathology 202: 145–156.
Riedemann, N.C., R.F. Guo, and P.A. Ward. 2003. The enigma of sepsis. Journal of Clinical Investigation 112: 460–467.
Strieter, R.M., S.L. Kunkel, M.P. Keane, and T.J. Standiford. 1999. Chemokines in lung injury: Thomas A Neff Lecture. Chest 116: 103S–110S.
Kitamura, Y., S. Hashimoto, N. Mizuta, A. Kobayashi, K. Kooguchi, I. Fujiwara, and H. Nakajima. 2001. Fas/Fasl-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice. American Journal of Respiratory and Critical Care Medicine 163: 762–769.
Wu, Y., M. Singer, F. Thouron, M. Alaoui-El-Azher, and L. Touqui. 2002. Effect of surfactant on pulmonary expression of type IIA PLA(2) in an animal model of acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 282: L743–L750.
Koller, K., and F. Schwarz. 2001. Formulation of valnemulin [P]. US:6284792.
Windsor, H.M., P.H. Ripley, P.C.T. Hannan 1996. An in vitro investigation of the sensitivity of German field isolates of M. hyopneumoniae and M. hyosynoviae to SDZ PMD 296, a new pleuromulin derivate. In: Proceedings of the 14th IPVS Congress, 226. Bologna, Italy.
Hannan, P.C., H.M. Windsor, and P.H. Ripley. 1997. in vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae. Research in Veterinary Science 63: 157–160.
Long, K.S., L.H. Hansen, L. Jakobsen, and B. Vester. 2006. Interaction of pleuromutilin derivatives with the ribosomal peptidyl transferase center. Antimicrobial Agents and Chemotherapy 50: 1458–1462.
Heilmann, C., L. Jensen, J.S. Jensen, K. Lundstrom, D. Windsor, H. Windsor, and D. Webster. 2001. Treatment of resistant Mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. Journal of Infection 43: 234–238.
Zhang, X., H. Li, H. Feng, H. Xiong, L. Zhang, Y. Song, L. Yu, and X. Deng. 2009. Valnemulin downregulates nitric oxide, prostaglandin E2, and cytokine production via inhibition of NF–kappaB and MAPK activity. International Immunopharmacology 9: 810–816.
Ysebaert, D.K., G.K.E. De, S.R. Vercauteren, M. Ghielli, G.A. Verpooten, E.J. Eyskens, and B.M.E. De. 2000. Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrology, Dialysis, Transplantation 15: 1562–1574.
Mongan, L.C., T. Jones, and G. Patrick. 2000. Cytokine and free radical responses of alveolar macrophages in vitro to asbestos fibres. Cytokine 12: 1243–1247.
Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. Journal of Experimental Medicine 189: 1777–1782.
Szarka, R.J., N. Wang, L. Gordon, P.N. Nation, and R.H. Smith. 1997. A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation. Journal of Immunological Methods 202: 49–57.
von Bismarck, P., K. Klemm, W.C.F. García, S. Winoto-Morbach, S. Schütze, and M.F. Krause. 2009. Selective NF–kappaB inhibition, but not dexamethasone, decreases acute lung injury in a newborn piglet airway inflammation model. Pulmonary Pharmacology and Therapeutics 22: 297–304.
Lucas, R., A.D. Verin, S.M. Black, and J.D. Catravas. 2009. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. Biochemical Pharmacology 77: 1763–1772.
Staub Sr., N.C., K.E. Longworth, V. Serikov, E.H. Jerome, and T. Elsasser. 2001. Detergent inhibits 70–90% of responses to intravenous endotoxin in awake sheep. Journal of Applied Physiology 90: 1788–1797.
Sone, Y., V.B. Serikov, and N.C. Staub Sr. 1999. Intravascular macrophage depletion attenuates endotoxin lung injury in anesthetized sheep. Journal of Applied Physiology 87: 1354–1359.
Mecklenburgh, K., J. Murray, T. Brazil, C. Ward, A.G. Rossi, and E.R. Chilvers. 1999. Role of neutrophil apoptosis in the resolution of pulmonary inflammation. Monaldi Archives for Chest Disease 54: 345–349.
Cavaillon, J.M., and M. Adib-Conquy. 2005. Monocytes/macrophages and sepsis. Critical Care Medicine 33: S506–S509.
Klebanoff, S.J. 2005. Myeloperoxidase: Friend and foe. Journal of Leukocyte Biology 77: 598–625.
Winterbourn, C.C., M.C. Vissers, and A.J. Kettle. 2000. Myeloperoxidase. Current Opinion in Hematology 7: 53–58.
Roth, E., N. Manhart, and B. Wessner. 2004. Assessing the antioxidative status in critically ill patients. Current Opinion in Clinical Nutrition and Metabolic Care 7: 161–168.
Ueda, J., M.E. Starr, H. Takahashi, J. Du, L.Y. Chang, J.D. Crapo, B.M. Evers, and H. Saito. 2008. Decreased pulmonary extracellular superoxide dismutase during systemic inflammation. Free Radical Biology and Medicine 45: 897–904.
Kinnula, V.L., and J.D. Crapo. 2003. Superoxide dismutases in the lung and human lung diseases. American Journal of Respiratory and Critical Care Medicine 167: 1600–1619.
Bhattacharyya, J., S. Biswas, and A.G. Datta. 2004. Mode of action of endotoxin: role of free radicals and antioxidants. Current Medicinal Chemistry 11: 359–368.
Fattman, C.L., L.M. Schaefer, and T.D. Oury. 2003. Extracellular superoxide dismutase in biology and medicine. Free Radical Biology and Medicine 35: 236–256.
Macdonald, J., H.F. Galley, and N.R. Webster. 2003. Oxidative stress and gene expression in sepsis. British Journal of Anaesthesia 90: 221–232.
Acknowledgments
This work was supported by a grant from the National Natural Science Foundation of China (No. 30671586).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Zhibao Chen and Xuemei Zhang contributed equally to this work.
Rights and permissions
About this article
Cite this article
Chen, Z., Zhang, X., Chu, X. et al. Preventive Effects of Valnemulin on Lipopolysaccharide-Induced Acute Lung Injury in Mice. Inflammation 33, 306–314 (2010). https://doi.org/10.1007/s10753-010-9186-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-010-9186-3